Therapy News and Research

RSS

GlaxoSmithKline starts phase III trial of Syncria (albiglutide) type 2 diabetes medication

GlaxoSmithKline has announced initiation and dosing of the first patient of the Phase III clinical trial programme to evaluate the efficacy, safety and tolerability of the investigational GLP-1 (Glucagon-like peptide 1) agonist Syncria (albiglutide) in men and women with type 2 diabetes.

18 Feb 2009

GABAergic system shows promise as molecular target for liver cancer therapy

Although GABA and GABA receptors function as an inhibitory neurotransmitter in the mature CNS, abnormal levels of gene and protein expression of some GABA receptor subunits have been detected in many malignant tumors, such as ð subunit in pancreatic cancer.

18 Feb 2009

Enzyme activates stress response and hypertrophy of the heart

An enzyme makes the mouse heart prone to chronic cardiac insufficiency – if it is suppressed, the heart remains strong despite increased stress.

18 Feb 2009

An adjuvant chemotherapeutic agent in gastric cancer therapy

Peritoneal carcinomatosis can be thought of as a series of events that together form a peritoneal metastatic cascade.

18 Feb 2009

A potential marker of increased histological activity in hepatitis C virus infection

Early, vigorous and sustained lymphocyte proliferative responses specific to hepatitis C virus (HCV) have been regarded as pivotal for viral clearance.

18 Feb 2009

Newly discovered mutation can hold the key to treat a large number of different cancers

Scientists have discovered a mutation responsible for cancer progression, a finding with potential implications for the development of treatment against not one, but a series of cancer types since this mutation can be linked to an abnormality recently discovered to exist in all malignancies.

18 Feb 2009

X-ray eyes bring us closer to early diagnosis of Parkinson's disease

It is estimated that 4 million people world-wide are suffering from Parkinson's, a complex disease that varies greatly among affected individuals.

17 Feb 2009

VAP cholesterol test helps find link between a rare gene mutation and heart protection

Using the VAP Cholesterol Test from Atherotech, Inc., University of Maryland researchers have found an association between a rare gene mutation and heart protection.

17 Feb 2009

Braconid parasite wasps have practiced gene therapy for a hundred million years

Braconid parasite wasps and their caterpillar hosts form a unique host-parasite model: the wasps lay their eggs inside the caterpillars and simultaneously inject some viral particles to get around the host's defenses and control its physiology.

17 Feb 2009

Hertfordshire to train new mental health workforce

The University's School of Social Community & Health Studies has won a three year contract worth one million pounds a year with the East of England Strategic Health Authority to implement training for a major government policy in mental health entitled Improving Access to Psychological Therapies (IAPT).

17 Feb 2009

Clot-buster boosts survival, decreases disability for deadly subset of stroke

New results from a multicenter study led by Johns Hopkins show that patients who got an experimental clot-busting treatment for a particularly lethal form of stroke were not only dramatically more likely to survive but also continued to shed lingering disabilities six months later.

16 Feb 2009

Boosting its infectivity turns benign virus into good gene therapy carrier for cystic fibrosis

Researchers from the University of California, Berkeley, and the University of Iowa have turned a relatively benign virus into a highly infectious form that is ideal as a carrier for gene therapy.

16 Feb 2009

Antimicrobial resistance in clinics, hospitals and at home

Antibiotic resistance and the rise of illnesses that cannot be treated easily because of drug resistance is a health concern around the world.

16 Feb 2009

Radioimmunotherapy shows promise for HIV infection and viral cancers

Scientists at Albert Einstein College of Medicine of Yeshiva University have piggybacked antibodies onto radioactive payloads to deliver doses of radiation that selectively target and destroy microbial and HIV-infected cells.

16 Feb 2009

New trial targets kidney cancer drug sorafenib in bladder cancer

According to the American Cancer Society, 69,000 cases of bladder cancer were diagnosed nationwide last year with some 2,600 new cases in New Jersey.

16 Feb 2009

Molecules self-assemble to provide new therapeutic treatments

Researchers in the laboratory of Samuel I. Stupp at Northwestern University have an interesting approach for tackling some major health problems: gather raw materials and then let them self-assemble into structures that can address a multitude of medical needs.

16 Feb 2009

New device decreases wait times for patients needing immunotherapy

Researchers from the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center have created a device that significantly decreases the time needed to produce genetically manipulated T cells in preclinical tests for leukemia.

16 Feb 2009

Breast cancer rates fall as women abandon HRT

Breast cancer rates among women in their 50s are falling at the same time as the number of women under 60 receiving prescriptions for hormone replacement (HRT) has halved according to Cancer Research UK.

16 Feb 2009

Avosentan shows prmoise for diabetic kidney disease

A new drug called avosentan significantly lowers urinary protein excretion-an important marker of kidney disease progression-in patients with diabetic kidney disease, according to an international clinical trial appearing in the March 2009 issue of the Journal of the American Society Nephrology (JASN).

16 Feb 2009